Teva Pharmaceuticals has reportedly lost a battle to have a generic form of its multiple sclerosis drug be blocked from entering the market 10 days before Teva’s patent expires.
According to reports, the Israel-based pharmaceutical company filed a lawsuit against the US Food and Drug Administration accusing the regulator of failing to prevent the generic form of Copaxone from going on sale in the US before Teva’s patent on the drug expired. But a federal judge threw out the suit this week, only days after it was filed.
Reports say Copaxone counts for more than 50 percent of Teva’s earnings.
This isn’t the first time Teva has fought to have generic, less expensive rivals from competing. Reports say the company has similarly challenged the release of drugs made by rivals Mylan and Novartis’s Sandoz.
The battle between brand name and generic pharmaceuticals has been a key focus of the Federal Trade Commission as of late; the agency is especially concerned with so-called pay-for-delay agreements, in which a brand name drug maker pays its generic rival to keep the cheaper competitor off store shelves.
Full content: Swiss Info
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI